This order is subject to initial advance payment as per the agreed terms of the contract and this order will be executed within 6 to 8 months.
This order is subject to initial advance payment as per the agreed terms of the contract
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
Themis will market this drug with the brand name REMITHEM.
The company is in the process of appointing the new Chief Financial Officer shortly and in the interim, Komal Gupta will continue as CFO
A pharma industry veteran with over three decades of experience in domestic as well as international markets
It dwells on colocating 157 nursing colleges with medical colleges and eliminating sickle cell anaemia by 2047
The Survey highlighted that Indian pharmaceutical exports achieved a healthy growth of 24 per cent in FY21 and expressed hope that India’s domestic pharmaceutical market is estimated to grow to US $65 billion by 2024 from estimated US $41 billion in 2021
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore
Subscribe To Our Newsletter & Stay Updated
